RVNC News and Press, Revance Therapeutics Inc. From 09/02/20

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, today announced that the company will participate in the Wells Fargo Securitie...

- Revance is positioned to introduce its innovative aesthetics portfolio, starting with the launch of the RHA® Collection, the first and only FDA-approved dermal fillers for correction of dynamic facial wrinkles and folds - - Clinical study results support the efficacy and safety ...

- The SAKURA 3 safety and efficacy results are consistent with those observed in SAKURA 1 and SAKURA 2 studies for DaxibotulinumtoxinA for Injection in the treatment of glabellar (frown) lines – Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innova...

Revance Therapeutics, Inc. (RVNC) Q2 2020 Earnings Conference Call August 06, 2020 04:30 PM ET Company Participants Jeanie Herbert - Head, Investor Relations & Corporate Communications Mark Foley - President & Chief Executive Officer Dustin Sjuts - Chief Commercial Office...

Revance Therapeutics (NASDAQ: RVNC ) : Q2 GAAP EPS of -$1.12 misses by $0.12 . More news on: Revance Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Conference Call Scheduled for Thursday, August 6, 2020 at 4:30 p.m. ET Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection, ...

Revance Therapeutics (NASDAQ: RVNC ) has completed its acquisition of privately-held Hint, Inc. doing business as HintMD. More news on: Revance Therapeutics, Inc., Healthcare stocks news, Read more ...

- Integrated fintech platform designed to transform existing payment processing ecosystems and improve both aesthetic practice economics and patient experiences - - Provides access to a $500+ million market opportunity in U.S. aesthetic practice payment services - Revance Therapeu...

Revance Therapeutics Reports Positive Results from Facial Skin Trial Revance Therapeutics ( RVNC ) reported positive data from its two Phase 2a clinical trials. Both the trials indicated that DaxibotulinumtoxinA or DAXI is efficacious as well as well tolerated. The first study sought to ...

- Enrollment closed with at least 76 subjects; study protocol modified in light of ongoing COVID-19 pandemic - - Revance now expects to report topline results from JUNIPER trial in early 2021 - Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovativ...